Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07450183 · ClinicalTrials.gov registry record · Phase 2
Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1
A Phase 2 study, sponsored by Henry Ford Health System.
- Not yet
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT07450183: Clinical Trial Phase 2 study, sponsored by Henry Ford Health System.
NCT07450183 is a Phase 2 study that has not yet begun recruiting, run by Henry Ford Health System. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07450183, a Phase 2 study, has not yet begun recruiting, sponsored by Henry Ford Health System.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a single arm phase II trial enrolling patients with stage II-IIIA non-small cell lung cancer whose disease is deemed amenable for surgical resection and has a PD-L1 level of ≥50%. Patients will receive cemiplimab for 3 cycles followed by surgical resection. The primary endpoint evaluated by the study is the amount of residual tumor in the resected tissue after 3 cycles of cemiplimab. After surgery, all patients will receive additional 10 cycles of cemiplimab and the treating oncologist will decide on the need of administering chemotherapy prior to that.
Interventions
- DRUG Cemiplimab
- DRUG Adjuvant chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 2 |
What is known before NCT07450183 opens enrollment
NCT07450183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which Cemiplimab is the first listed.
NCT07450183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07450183 about?
NCT07450183 is a clinical study titled "Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1". This is a single arm phase II trial enrolling patients with stage II-IIIA non-small cell lung cancer whose disease is deemed amenable for surgical resection and has a PD-L1 level of ≥50%. Patients will receive cemiplimab for 3 cycles followed by surgical resection. The primary endpoint evaluated by ...
What is the current status of trial NCT07450183?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2026-06-01. Estimated completion is 2027-12-01.
What interventions are being tested in trial NCT07450183?
The interventions under investigation include: Cemiplimab (DRUG), Adjuvant chemotherapy (DRUG).
Who is sponsoring clinical trial NCT07450183?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07450183's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI